Clinical Trials
389
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (338 trials with phase data)• Click on a phase to view related trials
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Non-small Cell Lung Cancer (NSCLC)Anaplastic Lymphoma Kinase (ALK) Positive
- Interventions
- First Posted Date
- 2025-08-24
- Last Posted Date
- 2025-09-17
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT07140016
- Locations
- 🇺🇸
Virginia Cancer Specialists PC, Fairfax, Virginia, United States
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-09-18
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT07024615
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Duke University Medical Center - Duke Cancer Center, Durham, North Carolina, United States
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
- Conditions
- Prostate CancerMetastatic Castration-Resistant Prostate CancerMetastatic Hormone Sensitive Prostate Cancer
- Interventions
- First Posted Date
- 2025-06-05
- Last Posted Date
- 2025-09-24
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 218
- Registration Number
- NCT07005154
- Locations
- 🇯🇵
Site JP81003, Sunto-gun, Shizuoka, Japan
🇺🇸New Mexico Oncology Hematology Consultants, Albuquerque, New Mexico, United States
🇺🇸Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or CancerMetastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Interventions
- Drug: Folinic acid (leucovorin or local equivalent)Drug: Placebo
- First Posted Date
- 2025-03-30
- Last Posted Date
- 2025-09-25
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT06901531
- Locations
- 🇺🇸
Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
🇺🇸Dana Farber/Harvard Cancer Center, Boston, Massachusetts, United States
🇺🇸The Center For Cancer And Blood Disorders (Texas Cancer Care), Fort Worth, Texas, United States
A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer
- Conditions
- Metastatic Urothelial Carcinoma
- Interventions
- Drug: Enfortumab Vedotin
- First Posted Date
- 2025-03-06
- Last Posted Date
- 2025-08-28
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06862219
- Locations
- 🇮🇳
Site IN91017, Dumas, Surat, India
🇮🇳Site IN91005, Varanasi, Uttar Pradesh, India
🇮🇳Site IN91012, Ahmedabad, India
- Prev
- 1
- 2
- 3
- 4
- 5
- 38
- Next